Every 10-Q that Gyre Therapeutics, Inc. (GYRE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GYRE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GYRE filings page.
Gyre Therapeutics, Inc., a commercial-stage biopharmaceutical company, reported revenue of $29,105 and $53,535 for the three and six months ended June 30, 2026, respectively (amounts in thousands). On May 4, 2026 it completed a common-control merger with Cullgen Inc., now a wholly owned subsidiary, and earlier periods have been retrospectively recast.
Operating expenses reached $43,468 in the quarter, including research and development of $14,300, related-party R&D of $4,836, selling and marketing of $13,754, and general and administrative of $7,867, plus transaction costs. Net loss attributable to common stockholders was $11,663 for the quarter and $24,809 year-to-date, compared with a $2,044 net loss and $126 of net income in the comparable 2025 periods, with basic and diluted loss per share of $0.12 and $0.26 for the three- and six‑month periods. Cash and cash equivalents were $43,287, alongside short-term bank deposits, short-term investments, and long-term certificates of deposit that supported total assets of $199,255 and equity of $142,489. Management states that existing liquidity, operating cash flows, and access to capital markets are expected to fund operations for at least twelve months. Revenue is concentrated in mainland China, with Sinopharm and two other distributors accounting for most pharmaceutical product sales, and a single partner generating all collaboration-based revenue.
Gyre Therapeutics, Inc. reported Q1 2026 revenue of $22.5 million, slightly above $22.1 million a year earlier, driven mainly by ETUARY, which contributed $21.0 million, or 93.1% of product sales. Newer products Contiva and Etorel added modest but growing contributions.
The company posted a net loss of $9.9 million, compared with net income of $3.7 million in Q1 2025, as selling, R&D, G&A and $2.6 million of transaction costs lifted operating expenses to $31.9 million. Despite the loss, operating cash flow was positive at $3.2 million, and cash and cash equivalents were $37.5 million as of March 31, 2026.
Total assets were $162.0 million and equity $137.0 million. Gyre’s China subsidiary remained the sole revenue source, while U.S. operations focused on Hydronidone development. After quarter-end, Gyre closed an all‑stock acquisition of Cullgen valued at approximately $300 million, bringing a new pipeline under common control accounting.
Gyre Therapeutics (GYRE) filed its Q3 2025 10‑Q, showing higher sales and continued profitability. Revenue rose to $30.6 million from $25.5 million a year ago, driven mainly by ETUARY, with added contributions from newly launched Contiva and Etolel. Operating income reached $6.9 million, and net income was $5.9 million for the quarter.
For the nine months, revenue was $79.4 million and net income $11.2 million. Cash and cash equivalents increased to $40.4 million from $11.8 million at year‑end, supported by $6.6 million of operating cash flow and a May 2025 underwritten offering that raised $23.0 million gross. Total assets were $159.4 million and total equity $137.4 million at quarter‑end.
Customer concentration remained notable, with Sinopharm accounting for roughly half of Q3 revenue and about half of accounts receivable as of quarter‑end. Intangible assets rose with the addition of Etolel technology rights (~$4.9 million), and the company recorded a lower warrant liability. As of October 31, 2025, 96,333,157 common shares were outstanding.
Gyre Therapeutics (GYRE) reported consolidated revenue of $26.8 million for the quarter and $48.8 million for the six months ended June 30, 2025, driven by Gyre Pharmaceuticals product sales. Net income was $1.58 million for the quarter and $5.31 million for six months; net income attributable to common stockholders was $0.44 million for the quarter and $3.14 million for six months. Cash and cash equivalents increased to $36.5 million on June 30, 2025, aided by a May 2025 underwritten offering that raised $23.0 million gross (net proceeds ~$21.3 million) and ATM proceeds of $0.5 million.
The company launched two products in 2025—Contiva (commercialization began March 2025) and Etorel (commercialization began June 2025); Etorel technology rights were recorded at ~$4.9 million. Total assets were $152.6 million and total equity $129.4 million. Management states existing liquidity and access to capital are expected to fund operations for at least 12 months. Key risks disclosed include heavy customer concentration (Sinopharm ~52% of revenue/accounts receivable), PRC cross-border restrictions and an accumulated deficit of $70.3 million.